So portfolio transformation, portion control and the right offerings will make sure that our brands stay relevant to those consumers.
This raises the intriguing possibility of a class effect, where GLP-1RAs could represent a novel therapeutic approach across multiple IMIDs, given the overlap in immunometabolic mechanisms common to these diseases
Mounjaro, whilst not licensed specifically for fatty liver disease, may be an appropriate option for eligible patients with type 2 diabetes or obesity who meet NICE criteria, potentially offering dual benefits for metabolic and hepatic health
recently reported that the glucoregulatory improvements of DPP-IV inhibitors are dependent on pancreatic proglucagon-derived factors in vivo (113), and furthermore, Omar et al
Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al
We then take those lab results and interpret them through the context of your storyyour personal experience